Is Medical Cannabis the New Epilepsy Treatment By: Altmed … Continue reading →

Hatfield, England (ots/PRNewswire) - PRESS RELEASE FOR EU MEDIA ONLY: NOT FOR SWISS/U.S. JOURNALISTS New Eisai office will support breast cancer treatment Halaven(R)(eribulin) and first-in-class epilepsy treatment Fycompa(R)(perampanel) Eisai today announces the official opening of a new office in Melbourne, Australia, which will further expand the company's geographical presence and increase patient reach. The Melbourne office will provide leading global research and development-based pharmaceutical company, Eisai, with an important platform from which its portfolio of novel oncology and epilepsy products will be marketed. The opening demonstrates Eisai's continuing commitment to improve access to innovative medicines in emerging economies and developing countries, as set out in the company's mid-term strategic plan. "The launch of the new Eisai office recognises that Australia has an important and distinctive healthcare system. We are delighted to broaden the reach of our innovative oncology and epilepsy products to benefit patients and their families in this key global market," commented Gary Hendler, President & CEO, Eisai EMEA. The expansion into Australia underscores Eisai's human health care (hhc) mission, the company's commitment to innovative solutions in disease prevention, cure and care for the health and wellbeing of people worldwide. The first two products to be supported by the … Continue reading →

HATFIELD, England, November 6, 2014 /PRNewswire/ -- Eisai announces with utmost disappointment that the German Federal Joint Committee (G-BA) has decided that the additional benefit for new generation anti-epileptic drug (AED) Fycompa (perampanel) has not been proven, when compared to conventional AEDs as defined by the G-BA.[1] The decision, based on methodological rather than clinical considerations, ignores the demands of the German Epilepsy Association (DE) and other epilepsy patient advocacy groups to recognise the additional benefit seen in practical applications as well as in studies.[2] The decision also ignores the recommendations of the German Society of Epileptology (DGfE) to assess the additional benefit of new AEDs. The efficacy and tolerability of adjunctive perampanel in the treatment of partial onset seizures in real world clinical practice has been demonstrated by a multi-centre, six-month observational study from nine epilepsy centres in Germany and Austria. The results show that half of the 281 people with highly refractory epilepsy treated with perampanel experienced at least a 50% reduction in seizure frequency and up to 15% became seizure free during the observation period.[3] "We are utterly disappointed by the decision of the German Joint Federal Committee (G-BA) not to recognise the additional benefit of perampanel … Continue reading →